Clinical Trial Diversity: ‘How Much More Evidence Do We Need To Move Forward?’
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks research ideas and plans to include demographic subgroup analyses in review templates as some stakeholders call for bolder action to change how companies conduct clinical trials.